1.
Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund K Bailey, Hoang Quan V, Saroj Namrata, Thompson Desmond
OphthalmologyMay 201555 citationsRandomized Controlled Trial
Aflibercept consistently caused less intraocular pressure elevation than ranibizumab in NVAMD patients, suggesting a lower glaucoma risk with aflibercept, which is clinically important for long-term treatment.